Historical and current perspectives on bone marrow transplantation for prevention and treatment of immunodeficiencies and autoimmunities

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 3, 2001, Pages 123-135

  Good, Robert A ^a   Verjee, Tazim ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; CANCER; CASE REPORT; CELL COMPOSITION; CELL DIFFERENTIATION; CELL INTERACTION; CHIMERA; CLINICAL RESEARCH; DIABETES MELLITUS; ENZYME DEFICIENCY; EXPERIMENTATION; GENETIC ENGINEERING; GRAFT REJECTION; HEREDITY; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFANT; INFORMATION SCIENCE; ISOGRAFT; LEUKEMIA; LONG TERM CARE; LYMPHATIC SYSTEM; LYMPHOMA; MALE; METABOLIC DISORDER; MOLECULAR GENETICS; MOUSE; NEW ZEALAND BLACK MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS; PRIMARY IMMUNE RESPONSE; REVIEW; SECONDARY IMMUNE RESPONSE; STROMA CELL; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THYMUS GRAFT; WHOLE BODY RADIATION;

EID: 0035073827     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2001.v7.pm11302546     Document Type: Article

References (136)

1. To the distinguished and elegant gentleman and experienced physician, Jan Vlackveld, of Haarlem (1657)
2. The Minnesota Scene: A crucial portal of entry to modern cellular immunology
3. Agammaglobulinemia
4. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells
5. Umbilical cord blood hematopoietic stem and repopulating cells in human clinical transplantation
6. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults
7. Mixed chimerism: Preclinical studies and clinical applications
8. The future of allogeneic hematopoietic stem cell transplantation: Minimizing pain, maximizing gain
9. T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years
10. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
11. Disturbances in gamma globulin synthesis as "experiments of nature."
12. Agammaglobulinemia: A provocative experiment of nature
13. Studies on agammaglobulinemia, II: Failure of plasma cell formation in the bone marrow and lymph nodes of patients with agammaglobulinemia
14. Absence of plasma cells from bone marrow and lymph nodes following antigenic stimulation in patients with agamma globulinemia
15. A clinical and experimental study of agammaglobulinemia
16. A clinical and experimental study of agammaglobulinemia
17. The gene involved in X-linked agammaglobulinemia is a member of the arc family of protein-tyrosine kinases
18. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
19. The pathogenesis of immunologic deficiency diseases
20. Assessment of the immune system
21. Definition of the gene loci in X-linked immunodeficiencies
22. The lesson of agammaglobulinemia 40 years after Bruton's discovery
23. Molecular and cellular aspects of X-linked agammaglobulinemia
24. BTKbase: A data base of XLA-causing mutations
25. BTKbase, mutation database for X-linked agammaglobulinemia (XLA)
26. X-linked agammaglobulinemia presenting as transient hypogammaglobulinemia of infancy
27. Absence of serum gamma globulins
28. Immunological deficiency diseases: Agammaglobulinemia, hypogammaglobulinemia, Hodgkin's disease and sarcoidosis
29. Recurrent bacterial infections and dysgammaglobulinemia: Deficiency of 75 gamma-globulins in the presence of elevated 19S gammaglobulins: Report of two cases
30. Primary immunodeficiency disease due to defects in lymphocytes
31. The primary immunodeficiencies
32. Immunodeficiency with Hyper-IgM (HIM)
33. X-linked immunodeficiency with increased IgM: Clinical, ethnic and immunologic heterogeneity
34. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome
35. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome
36. Defective expression of T cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM
37. Brief report: CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM
38. Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM
39. Signaling through CD40 rescues IgE but not IgG or IgA secretion in X-linked immunodeficiency with hyper-IgM
40. Immunologic reconstitution following bone marrow transplantation for X-linked hyper IgM syndrome
41. Prenatal test for X-linked severe combined immunodeficiency by analysis of maternal X-chromosome inactivation and linkage analysis
42. Immunological reconstitution of sex-linked lymphopenic immunological deficiency
43. Successful marrow transplantation for correction 1 deficit in lymphopenic agammaglobulinemia and treatment of immunologically induced pancytopenia
44. Immunologic reconstitution: The achievement and its meaning
45. Progress toward a cellular engineering
46. Gene therapy for primary immunodeficiency disease
47. Prospects for human gene therapy
48. Combined immunodeficiency disease associated with adenosine deaminase deficiency
49. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity
50. Development of gene therapy for immunodeficiency: Adenosine deaminase deficiency
51. Molecular cloning of human adenosine deaminase gene sequences
52. Isolation of cDNA clones for human adenosine deaminase
53. Cloning of cDNA sequences of human adenosine deaminase
54. A new chance for SCID gene therapy
55. Gene therapy in transplantation in the year 2000: Moving towards clinical applications?
56. Gene therapy: The first decade
57. Discussions on new concept of cellular basis of immunity. Peterson and Good
58. The functions of the thymus system and the bursa system in the chicken
59. The pathogenesis of immunologic deficiency diseases
60. Delineation of the thymic and bursal lymphoid systems in the chicken
61. A new concept of the cellular basis of immunity
62. The immunological role of different lymphoid organs in the chicken. I. Dissociation of immunological responsiveness
63. The two-component concept of the lymphoid system
64. Congenital absence of the thymus and its immunologic consequences: Concurrence with congenital hypoparathyroidism
65. The mammalian homologue of the avian bursa of Fabricius, I: Neonatal extirpation of Peyer's patch-type lymphoepithelial tissues in rabbits: Method and inhibition of development of humoral immunity
66. The role of the thymus in neonatal life
67. Studies on a fatal wasting syndrome of mice thymectomized at birth
68. Development of T-cell function after post-natal thymic transplantation for DiGeorge syndrome
69. Transplantation of the thymus tissue in complete DiGeorge syndrome
70. Para-influenza pneumonia in DiGeorge syndrome two years after thymic epithelial transplantation
71. Extraintestinal rotavirus infections in children with immunodeficiency
72. T cell receptor gene deletion circles identify recent thymic emigrants in the peripheral T cell pool
73. Foetal thymic transplant in a case of DiGeorge's syndrome
74. Implantation of a fetal thymus restoring immunological competence in a patient with thymus aplasia (DiGeorge's syndrome)
75. Immunological restitution in lymphopenic immunologic deficiency syndrome
76. Recombination within the HL-A locus
77. Bone marrow transplantation: Cellular engineering to correct primary immunodeficiency, aregenerative anemia and pancytopenia
78. Follow-up of correction of severe dual system immunodeficiency with bone marrow transplantation
79. Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation
80. Humoral and cell-mediated immune responses in fully allogeneic bone marrow chimera in mice
81. Rationale for bone marrow transplantation in the treatment of autoimmune diseases
82. Prevention of type I diabetes in non-obese diabetic mice by allogenic bone marrow transplantation
83. Successful liver allografts in mice by combination with allogeneic bone marrow transplantation
84. Treatment of type 1 diabetes mellitus in non-obese diabetic mice by transplantation of allogeneic bone marrow and pancreatic tissue
85. The prospects for BMT-from mouse to human
86. Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation: Complete prevention of recurrence of autoimmune diseases in MRL/lpr mice by transplantation of (stromal cells) from the same donor
87. Successful bone marrow transplantation by bone grafts in chimeric-resistant combination
88. Prevention of autoimmune inflammatory polyarthritis in male New Zealand Black/Kn mice by transplantation of bone marrow cells plus bone (stromal cells)
89. Bone marrow transplantation for autoimmune disease
90. Thymus transplantation a critical factor for correction of autoimmune disease in aging MRL/+ mice
91. The pathogenesis of autoimmunity in New Zealand mice
92. Intense immune suppression for systemic lupus: The role of hematopoietic stem cells
93. Anticardiolipin antibodies in NZW × BXSB F1 mice: A model of antiphospholipid syndrome
94. 1 mice by haploidentical bone marrow transplantation: Possible role for anticardiolipin autoantibodies
95. A clinical and immunopathological dissection of rapidly progressive glomerulonephritis
96. Rapidly progressive glomerulonephritis: Classification, pathogenetic mechanisms, and therapy
97. Genetic selection for crescent formation yields mouse strain with rapidly progressive glomerulonephritis and small vessel vasculitis
98. Prevention of crescentic glomerulonephritis in SCG/Kj mice by bone marrow transplantation
99. Characterization of mixed allogeneic chimeras, immunocompetence, in vitro reactivity and genetic specificity of tolerance
100. Induction of immunological tolerance in full major and multiminor histocompatibility-disparate mice using a mixed bone marrow transplantation model
101. Prevention of development of autoimmune disease in BXSB mice by mixed bone marrow transplantation
102. Studies on the mechanisms of the development of lupus nephritis in BXSB mice, I: Analysis of immunological abnormalities at the onset period
103. A Y chromosome associated factor in strain BXSB producing accelerated autoimmunity and lymphoproliferation
104. Effective treatment of autoimmune disease and progressive renal disease by mixed bone marrow transplantation that establishes a stable mixed chimerism in BXSB recipient mice
105. Osteoblasts promote engraftment of allogeneic hematopoietic stem cells
106. Successful prevention of autoimmune disease by transplantation of adequate number of fully allogeneic hematopoietic stem cells
107. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice
108. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen
109. Mixed chimerism as an approach to transplantation tolerance
110. Towards the goal of inducing transplantation tolerance
111. Long-term immunologic tolerance induction in chimeric mice after bone marrow transplantation across major histocompatibility barriers: Persistent or redeveloping immunologic responsiveness after prolonged survival
112. Successful pancreatic allografts in combination with bone marrow transplantation in mice
113. Accommodation of vascularized xenografts expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment
114. CD28-B7 blockade after allogeneic challenge in vivo inhibits Th1 cytokines but spares Th2
115. A new strategy for organ allografts without using immunosuppressants and irradiation
116. Induction of donor-specific T cell energy by portal venous injection of allogeneic cells
117. Fate of allogeneic or syngeneic cells in intravenous or portal vein injection: Possible explanation for the mechanism of tolerance induction by portal vein injection
118. Acceptance of skin allografts in pigs by portal venous injection of donor bone marrow cells
119. Acceptance of skin xenografts (from guinea pig to mice) by portal venous and intravenous injections of donor hematolymphoid cells
120. Xenotransplantation: Application of disease resistance
121. Heterotransplantation of the kidney: Two clinical experiences
122. Reversal of early graft rejection after renal heterotransplantation in man
123. Renal heterotransplantation from baboon to man: Experience with 6 cases
124. Renal heterotransplantation from baboon to man: Experience with 6 cases
125. Current and future prospects for xenotransplantation
126. Characterization of the human antiporcine immune response: A prerequisite to xenotransplantation
127. Rationale for transplantation of both allogeneic bone marrow and stromal cells in the treatment of autoimmune diseases
128. Marrow transplantation from tolerant donors to treat and prevent autoimmune diseases in BXSB mice
129. Autoimmune diseases as stem cell disorders
130. Preclinical investigations that subserve efforts to employ bone marrow transplantation for rheumatoid or autoimmune diseases
131. Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells
132. + hematopoietic cells to prevent or induce systemic autoimmune disease
133. Prevention of coronary vascular disease by transplantation of T cell depleted bone marrow and hematopoietic stem cell preparation in autoimmune-prone W/BF1 mice